

Kristie A Blum

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9206275/publications.pdf>

Version: 2024-02-01

84
papers

4,171
citations

331259

21
h-index

114278

63
g-index

84
all docs

84
docs citations

84
times ranked

5095
citing authors

#	ARTICLE	IF	CITATIONS
1	Relevance of Bone Marrow Biopsies for Response Assessment in US National Cancer Institute National Clinical Trials Network Follicular Lymphoma Clinical Trials. <i>Journal of Clinical Oncology</i> , 2023, 41, 336-342.	0.8	9
2	Improving eligibility criteria for first-line trials for patients with DLBCL using a US-based Delphi-method survey. <i>Blood Advances</i> , 2022, 6, 2745-2756.	2.5	3
3	Humoral Responses Against SARS-CoV-2 and Variants of Concern After mRNA Vaccines in Patients With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 3020-3031.	0.8	26
4	End of induction positron emission tomography complete response (PET- α CR) as a surrogate for progression-free survival in previously untreated follicular lymphoma. <i>British Journal of Haematology</i> , 2022, 198, 333-337.	1.2	2
5	Burkitt lymphoma in the modern era: real-world outcomes and prognostication across 30 US cancer centers. <i>Blood</i> , 2021, 137, 374-386.	0.6	59
6	Burkitt Lymphoma International Prognostic Index. <i>Journal of Clinical Oncology</i> , 2021, 39, 1129-1138.	0.8	37
7	Intensive induction regimens after deferring initial therapy for mantle cell lymphoma are not associated with improved survival. <i>European Journal of Haematology</i> , 2021, 107, 301-310.	1.1	3
8	HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis. <i>Blood Advances</i> , 2021, 5, 2852-2862.	2.5	24
9	Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy. <i>Blood Advances</i> , 2021, 5, 5179-5189.	2.5	21
10	PK and PD Assessment of BET Inhibitor Pelabresib (CPI-0610) in Patients with Relapsed or Refractory Lymphoma: Findings from a Phase 1 Study. <i>Blood</i> , 2021, 138, 1202-1202.	0.6	3
11	Gemcitabine and bendamustine is a safe and effective salvage regimen for patients with recurrent/refractory Hodgkin lymphoma: Results of a phase 1/2 study. <i>Cancer</i> , 2020, 126, 1235-1242.	2.0	8
12	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance). <i>Cancer</i> , 2019, 125, 3378-3389.	2.0	10
13	Febrile Hypotensive Reactions Following ABVD Chemotherapy in Patients With EBV-associated Classical Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e123-e128.	0.2	1
14	The prognostic significance of PFS24 in follicular lymphoma following firstline immunotherapy: A combined analysis of 3 CALGB trials. <i>Cancer Medicine</i> , 2019, 8, 165-173.	1.3	27
15	The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC). <i>Blood</i> , 2019, 134, 397-397.	0.6	3
16	Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-World Analysis. <i>Blood</i> , 2019, 134, 402-402.	0.6	9
17	Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2018, 4, 712.	3.4	20
18	Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. <i>Cancer</i> , 2018, 124, 2306-2315.	2.0	40

#	ARTICLE	IF	CITATIONS
19	Treatment-Resistant Hodgkin Lymphoma. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 244-248.	1.0	3
20	Incidence and outcomes of lymphoid malignancies in adolescent and young adult patients in the United States. <i>British Journal of Haematology</i> , 2018, 183, 385-399.	1.2	24
21	Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. <i>Blood</i> , 2018, 132, 3133-3133.	0.6	11
22	Intensive Induction Regimens after Deferring Initial Therapy Are Not Associated with Improved Progression-Free or Overall Survival in Patients with Mantle Cell Lymphoma (MCL). <i>Blood</i> , 2018, 132, 4153-4153.	0.6	0
23	A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2268-2269.	0.6	4
24	ChR2 but not R2HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG Study S1106. <i>British Journal of Haematology</i> , 2017, 176, 759-769.	1.2	40
25	Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH. <i>British Journal of Haematology</i> , 2017, 179, 739-747.	1.2	101
26	Retrospective analysis of bendamustine and rituximab use in indolent and mantle cell non-Hodgkin lymphoma based on initial starting dose. <i>Leukemia and Lymphoma</i> , 2017, 58, 1589-1597.	0.6	2
27	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	2.5	62
28	Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. <i>Blood Advances</i> , 2017, 1, 1739-1748.	2.5	123
29	Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission. <i>Journal of Clinical Oncology</i> , 2017, 35, 2260-2267.	0.8	132
30	Association of FDG PET-CT (PET) avid skeletal lesions (SL) with progression-free survival (PFS) in patients (pts) with previously untreated follicular lymphoma (FL).. <i>Journal of Clinical Oncology</i> , 2017, 35, e19026-e19026.	0.8	0
31	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	3.0	56
32	Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103. <i>Blood</i> , 2016, 128, 2510-2516.	0.6	56
33	Sole rearrangement but not amplification of MYC is associated with a poor prognosis in patients with diffuse large B cell lymphoma and B cell lymphoma unclassifiable. <i>British Journal of Haematology</i> , 2016, 175, 631-640.	1.2	55
34	the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. <i>Blood</i> , 2016, 128, 55-55.	0.6	8
35	Deferred treatment as a viable option for selected patients with mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7567-7567.	0.8	1
36	Subgroup analyses of diffuse large B-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin lymphoma (R-R NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7545-7545.	0.8	0

#	ARTICLE	IF	CITATIONS
37	B-cell receptor pathway modulators in NHL. Hematology American Society of Hematology Education Program, 2015, 2015, 82-91.	0.9	15
38	Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. JAMA Oncology, 2015, 1, 80.	3.4	498
39	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nature Medicine, 2015, 21, 922-926.	15.2	927
40	Complex Karyotype Is Associated With Aggressive Disease and Shortened Progression-Free Survival in Patients With Newly Diagnosed Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 278-285.e1.	0.2	19
41	A Phase I Study of Gemcitabine and Bendamustine in Relapsed/Refractory Hodgkin Lymphoma. Blood, 2015, 126, 1496-1496.	0.6	1
42	Bortezomib Maintenance (BM) Versus Consolidation (BC) Following Aggressive Immunochemotherapy and Autologous Stem Cell Transplant (ASCT) for Untreated Mantle Cell Lymphoma (MCL): CALGB (Alliance) 50403. Blood, 2015, 126, 337-337.	0.6	23
43	Updated Results of a Phase I Study of Ibrutinib and Lenalidomide in Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. Blood, 2015, 126, 3983-3983.	0.6	5
44	Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma (Alliance 051103). Blood, 2015, 126, 471-471.	0.6	15
45	A Phase I Study of BKM120 (Buparlisib) and Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NHL). Blood, 2015, 126, 5114-5114.	0.6	2
46	Pre-Transplant R-Bendamustine Induces High Rates of Minimal Residual Disease in MCL Patients: Updated Results of S1106: US Intergroup Study of a Randomized Phase II Trial of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplants for Patients with Mantle Cell Lymphoma. Blood, 2015, 126, 518-518.	0.6	5
47	Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10A002. British Journal of Haematology, 2014, 165, 102-111.	1.2	78
48	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncology, The, 2014, 15, 48-58.	5.1	438
49	Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood, 2014, 124, 2354-2361.	0.6	382
50	CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.. Journal of Clinical Oncology, 2014, 32, 8521-8521.	0.8	12
51	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Monotherapy Demonstrates Long-Term Safety and Durability Of Response In Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) Patients In An Open-Label Extension Study. Blood, 2013, 122, 4163-4163.	0.6	9
52	Evaluation Of a Novel 3 Factor Prognostic Score (PS-3) For Patients With Advanced Hodgkin Lymphoma (HL) Treated On US Intergroup E2496. Blood, 2013, 122, 4277-4277.	0.6	3
53	Mature Response Data From a Phase 2 Study Of PI3K-Delta Inhibitor Idelalisib In Patients With Double (Rituximab and Alkylating Agent)-Refractory Indolent B-Cell Non-Hodgkin Lymphoma (iNHL). Blood, 2013, 122, 85-85.	0.6	10
54	Gray Zone Lymphoma (GZL) With Features Intermediate Between Classical Hodgkin Lymphoma (cHL) and Diffuse Large B-Cell Lymphoma (DLBCL): A Large Retrospective Multicenter Analysis Of Clinical Characteristics, Treatment, Outcomes, and Prognosis In The Current Era. Blood, 2013, 122, 847-847.	0.6	2

#	ARTICLE	IF	CITATIONS
55	Phase 1 Study of TRU-016, An Anti-CD37 SMIP α , β Protein in Relapsed and/or Refractory NHL Patients. Blood, 2011, 118, 1636-1636.	0.6	2
56	Results of A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma. Blood, 2011, 118, 3707-3707.	0.6	0
57	Phase I trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: dose-limiting myelosuppression without evidence of DNA hypomethylation. British Journal of Haematology, 2010, 150, 189-195.	1.2	59
58	Upcoming Diagnostic and Therapeutic Developments in Classical Hodgkin's Lymphoma. Hematology American Society of Hematology Education Program, 2010, 2010, 93-100.	0.9	9
59	Response, Progression-Free Survival, and Overall Survival of Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Treated with Flavopiridol: Impact of Poor Risk Cytogenetic Abnormalities. Blood, 2010, 116, 2456-2456.	0.6	1
60	Flavopiridol Treatment of Patients Aged 70 or Older with Refractory or Relapsed Chronic Lymphocytic Leukemia Is Feasible and Not Associated with Adverse Outcome When Compared to Younger Patients. Blood, 2010, 116, 1378-1378.	0.6	0
61	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 349-356.	0.6	12
62	Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphoma. Leukemia and Lymphoma, 2009, 50, 1232-1234.	0.6	0
63	A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. Blood, 2009, 114, 3693-3693.	0.6	12
64	Flavopiridol, Fludarabine and Rituximab (FFR): An Active Regimen in Indolent B-Cell Lymphoproliferative Disorders and Mantle Cell Lymphoma. Blood, 2008, 112, 1571-1571.	0.6	1
65	Serious Pulmonary Toxicity with SGN-30 and Gemcitabine, Vinorelbine, and Liposomal Doxorubicin in Patients with Relapsed/Refractory Hodgkin Lymphoma (HL): Cancer and Leukemia Group B (CALGB) 50502. Blood, 2008, 112, 232-232.	0.6	7
66	A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma. Blood, 2008, 112, 3053-3053.	0.6	1
67	Evaluation of the Pharmacokinetics, Immunogenicity, and Safety of XmAb $\hat{\text{A}}$ 2513 in the Ongoing Study XmAb2513-01: A Phase 1 Study of Every Other Week XmAb2513 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Patients with Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma. Blood, 2008, 112, 5012-5012.	0.6	6
68	A Phase I Evaluation of Low Dose Decitabine Targeting DNA Hypermethylation in Patients with Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL): Dose-Limiting Myelosuppression without Evidence of Hypomethylation. Blood, 2008, 112, 3169-3169.	0.6	0
69	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkin's Lymphomas. Blood, 2008, 112, 3265-3265.	0.6	0
70	Computed Tomography Scans Do Not Improve the Predictive Power of 1996 National Cancer Institute's Sponsored Working Group Chronic Lymphocytic Leukemia Response Criteria. Journal of Clinical Oncology, 2007, 25, 5624-5629.	0.8	21
71	Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leukemia and Lymphoma, 2007, 48, 1313-1319.	0.6	64
72	del(17p13.1) in Chronic Lymphocytic Leukemia Confers Poor Prognosis Even at Low Percentage Involvement and Increases Proportionately with Increase in Clonal Involvement. Blood, 2007, 110, 2073-2073.	0.6	1

#	ARTICLE	IF	CITATIONS
73	Preliminary Results of a Phase II Study of Flavopiridol (Alvocidib) in Relapsed Chronic Lymphocytic Leukemia (CLL): Confirmation of Clinical Activity in High-Risk Patients and Achievement of Complete Responses (CR).. Blood, 2007, 110, 3104-3104.	0.6	3
74	Low Incidence of Opportunistic Infections in CLL Patients Treated with Single Agent Flavopiridol.. Blood, 2007, 110, 3128-3128.	0.6	5
75	Prolonged follow-up after initial therapy with 2-chlorodeoxyadenosine in patients with indolent non-Hodgkin lymphoma. Cancer, 2006, 107, 2817-2825.	2.0	20
76	Flavopiridol Can Be Safely Dose Escalated in Relapsed CLL Patients: Achievement of Target Cmax Results in Improved Clinical Activity.. Blood, 2006, 108, 2845-2845.	0.6	4
77	Flavopiridol Is Active in Genetically High-Risk, Relapsed Chronic Lymphocytic Leukemia (CLL): Analysis of 56 Patients by Cytogenetic Abnormality.. Blood, 2006, 108, 302-302.	0.6	6
78	Excessive Neurotoxicity in a Phase II Trial of Combined Bortezomib and Rituximab in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma.. Blood, 2006, 108, 2768-2768.	0.6	0
79	The Addition of CT Scans to NCI-96 Chronic Lymphocytic Leukemia (CLL) Response Criteria Fails To Improve the Predictive Power of Complete Response (CR) and Partial Response (PR) as Assessed by Improvement in Progression-Free (PFS) and Overall Survival (OS) .. Blood, 2006, 108, 2833-2833.	0.6	0
80	Combination Bortezomib (PS341, Velcade) and Rituximab Treatment Affects Multiple Survival and Death Pathways To Promote Apoptosis in Mantle Cell Lymphoma.. Blood, 2005, 106, 2407-2407.	0.6	5
81	Successful Management (Mgt) of Hyperkalemia Associated with Tumor Lysis Syndrome (TLS) in Refractory Chronic Lymphocytic Leukemia (CLL) Patients (pts) Receiving Flavopiridol on an Active Pharmacologically Derived Schedule.. Blood, 2005, 106, 2124-2124.	0.6	1
82	90Yttrium-ibritumomab tiuxetan: a novel treatment for non-Hodgkin's lymphoma. Expert Opinion on Biological Therapy, 2004, 4, 1323-1331.	1.4	0
83	Adult Burkitt leukemia and lymphoma. Blood, 2004, 104, 3009-3020.	0.6	487
84	Flavopiridol Administered as a Pharmacologically-Derived Schedule Demonstrates Marked Clinical Activity in Refractory, Genetically High Risk, Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 341-341.	0.6	17